<DOC>
<DOCNO>
EP-0000053
</DOCNO>
<TEXT>
<DATE>
19781220
</DATE>
<IPC-CLASSIFICATIONS>
C07K-7/56 A61P-3/02 C07K-1/113 C07K-14/435 A61K-38/04 C07K-1/00 C07K-7/00 C07K-14/655 C07K-14/575 A61P-3/00 <main>C07C-103/52</main> A61K-37/02 A61K-38/00 
</IPC-CLASSIFICATIONS>
<TITLE>
somatostatin analogs, process for their preparation and pharmaceutical compositions containing them.
</TITLE>
<APPLICANT>
merck & co incus<sep>merck & co. inc.<sep>merck &amp; co., inc.126, east lincoln avenue p.o. box 2000rahway new jersey 07065-0900us<sep>merck & co. inc.<sep>
</APPLICANT>
<INVENTOR>
veber daniel frank<sep>veber, daniel frank<sep>veber, daniel frank290 batleson roadambler, pennsylvaniaus<sep>veber, daniel frank<sep>veber, daniel frank290 batleson roadambler, pennsylvaniaus<sep>
</INVENTOR>
<ABSTRACT>
somatostatin analogs having the structural formula:    wherein   a is phe, tyr, o-me-tyr,   b is phe, tyr,   c is thr, val,   wherein the ring formed by the peptide backbone contains  26 atoms and pharmaceutically acceptable non-toxic acid  addition salts thereof are prepared by the solid phase  method.  these peptides have the property of inhibiting  release of insulin, inhibiting growth hormone release and  inhibiting glucagon release in humans and animals without  materially affecting gastric secretion.  
</ABSTRACT>
</TEXT>
</DOC>
